Pulmonary delivery of respiratory syncytial virus DNA vaccines using macroaggregated albumin particles

Vaccine

Volumn 22, Issue 17-18, 2004, Pages 2248-2260

  Harcourt, Jennifer L ^a   Anderson, Larry J ^a   Sullender, Wayne ^b   Tripp, Ralph A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Macroaggregated albumin; Respiratory syncytial virus (RSV); Vaccination

Indexed keywords

ALBUMIN; ANTIBODY; CYTOKINE; DNA VACCINE; GLYCOPROTEIN F; GLYCOPROTEIN F ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; GENETIC CODE; IMMUNITY; LOW DRUG DOSE; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; TH1 CELL; TH2 CELL; VACCINATION; VIRUS INFECTION; VIRUS TITRATION;

ADMINISTRATION, INTRANASAL; ALBUMINS; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, CD3; BRONCHOALVEOLAR LAVAGE FLUID; CYTOKINES; FEMALE; LEUKOCYTES; LUNG; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VACCINATION; VACCINES, DNA; VIRAL PROTEINS;

EID: 2442535997     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.050     Document Type: Article

References (49)

1. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163(4):1991;693-698
2. Falsey A.R., Treanor J.J., Betts R.F., Walsh E.E. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40(2):1992;115-119
3. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epidemiol. 89(4):1969;405-421
4. Waris M.E., Tsou C., Erdman D.D., Zaki S.R., Anderson L.J. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J. Virol. 70(5):1996;2852-2860
5. Srikiatkhachorn A., Braciale T.J. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J. Virol. 71(1):1997;678-685
6. Englund J.A. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody. Pediatr. Infect. Dis. J. 13(5):1994;449-453
7. Karron R.A., Wright P.F., Crowe J.E. Jr., Clements-Mann M.L., Thompson J., Makhene M. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J. Infect. Dis. 176(6):1997;1428-1436
8. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe J.E. Jr., Boyce T.G., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182(5):2000;1331-1342
9. Alymova I.V., Kodihalli S., Govorkova E.A., Fanget B., Gerdil C., Webster R.G. Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs. J. Virol. 72(5):1998;4472-4477
10. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18:2000;927-974
11. McCluskie M.J., Brazolot Millan C.L., Gramzinski R.A., Robinson H.L., Santoro J.C., Fuller J.T., et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med. 5(5):1999;287-300
12. Cusi M.G., Zurbriggen R., Valassina M., Bianchi S., Durrer P., Valensin P.E., et al. Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity. Virology. 277(1):2000;111-118
13. Okada E., Sasaki S., Ishii N., Aoki I., Yasuda T., Nishioka K., et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 159(7):1997;3638-3647
14. McCluskie M.J., Chu Y., Xia J.L., Jessee J., Gebyehu G., Davis H.L. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev. 8(5):1998;401-414
15. Krieg A.M., Kline J.N. Immune effects and therapeutic applications of CpG motifs in bacterial DNA. Immunopharmacology. 48(3):2000;303-305
16. Tripp R.A., Jones L., Anderson L.J., Brown M.P. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse. J. Immunol. 164(11):2000;5913-5921
17. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicolson C., Melero J.A., Taylor G. DNA encoding the attachment (G) or fusion (F) protein of respiratory syncytial virus induces protection in the absence of pulmonary inflammation. J. Gen. Virol. 81(Part 10):2000;2519-2523
18. Connors M., Collins P.L., Firestone C.Y., Murphy B.R. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J. Virol. 65(3):1991;1634-1637
19. Power U.F., Nguyen T.N., Rietveld E., de Swart R.L., Groen J., Osterhans A.D., et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184(11):2001;1456-1460
20. Bembridge G.P., Rodriguez N., Garcia-Beato R., Nicolson C., Melero J.A., Taylor G. Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine. 19(9-10):2000;1038-1046
21. Yoshida A., Nagata T., Uchijima M., Higashi T., Koide Y. Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses. Vaccine. 18(17):2000;1725-1729
22. Iqbal M., Lin W., Jabbal-Gill I., Davis S.S., Steward M.W., Illum L. Nasal delivery of chitosan-DNA plasmid expressing epitopes of respiratory syncytial virus (RSV) induces protective CTL responses in BALB/c mice. Vaccine. 21(13-14):2003;1478-1485
23. Mohapatra S.S. Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus. Pediatr. Infect. Dis. J. 22(Suppl 2):2003;S100-S103. [discussion S03-4]
24. Colombetti L.G., Moerlien S., Pinsky S. Rapid and reliable preparation of macroaggregated albumin suitable for lung scintigraphy. Int. J. Nucl. Med. Biol. 2(4):1975;180-184
25. Orson F.M., Kinsey B.M., Hua P.J., Bhogal B.S., Densmore C.L., Barry M.A. Genetic immunization with lung-targeting macroaggregated polyethyleneimine- albumin conjugates elicits combined systemic and mucosal immune responses. J. Immunol. 164(12):2000;6313-6321
26. Hapke E.J., Pederson H.J. Ultrastructural changes in rat lungs induced by radioactive macroaggregated albumin. Am. Rev. Respir. Dis. 100(2):1969;194-205
27. DeLand F.H. The fate of macroaggregated albumin used in lung scanning. J. Nucl. Med. 7(12):1966;883-895
28. Makrigiorgos G.M., Adelstein S.J., Kassis A.I. Cellular radiation dosimetry and its implications for estimation of radiation risks. Illustrative results with technetium 99m-labeled microspheres and macroaggregates. JAMA. 264(5):1990;592-595
29. Wang H., Griffiths M.N., Burton D.R., Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc. Natl. Acad. Sci. U.S.A. 97(2):2000;847-852
30. Gautam A., Densmore C.L., Xu B., Waldrep J.C. Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol. Ther. 2(1):2000;63-70
31. Densmore C.L., Orson F.M., Xu B., Kinsey B.M., Waldrep J.C., Hua P., et al. Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization. Mol. Ther. 1(2):2000;180-188
32. Tripp R.A., Moore D., Jones L., Sullender W., Winter J., Anderson L.J. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73(9):1999;7099-7107
33. Sullender W. Antigenic analysis of chimeric and truncated G proteins of respiratory syncytial virus. Virology. 209(1):1995;70-79
34. Piedra P.A., Camussi G., Ogra P.L. Immune response to experimentally induced infection with respiratory syncytial virus: possible role in the development of pulmonary disease. J. Gen. Virol. 70(Part 2):1989;325-333
35. Tripp R.A., Anderson L.J. Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine. J. Virol. 72(11):1998;8971-8975
36. Tripp R.A., Moore D., Winter J., Anderson L.J. Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice. J. Virol. 74(4):2000;1614-1622
37. Richardson L.S., Yolken R.H., Belshe R.B., Camargo E., Kim H.W., Chanock R.M. Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection. Infect. Immun. 20(3):1978;660-664
38. Tripp R.A., Jones L.P., Haynes L.M., Zheng H., Murphy P.M., Anderson L.J. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2(8):2001;732-738
39. + T cells develop greater numbers of IgA-producing cells in response to a respiratory virus infection. Virology. 204(1):1994;234-241
40. Taylor G., Stott E.J., Hughes M., Collins A.P. Respiratory syncytial virus infection in mice. Infect. Immun. 43(2):1984;649-655
41. Knowles M.R., Hohneker K.W., Zhou Z., Olsen J.C., Noah T.L., Hu P.C., et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N. Engl. J. Med. 333(13):1995;823-831
42. + cells. J. Immunol. 160(3):1998;1158-1165
43. Arase H., Saito T., Phillips J.H., Lanier L.L. Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2). J. Immunol. 167(3):2001;1141-1144
44. Hancock G.E., Heers K.M., Smith J.D., Scheuer C.A., Ibraghimov A.R., Pryharski K.S. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine. 19(32):2001;4874-4882
45. + T cell responses. J. Immunol. 166(2):2001;1106-1113
46. Klinguer C., Beck A., De-Lys P., Bussat M.C., Blaecke A., Deronet F., et al. Lipophilic quaternary ammonium salt acts as a mucosal adjuvant when co-administered by the nasal route with vaccine antigens. Vaccine. 19(30):2001;4236-4244
47. Magnusson M., Johansson E., Berg M., Eloranta M.L., Fuxler L., Fossum C. The plasmid pcDNA3 differentially induces production of interferon-alpha and interleukin-6 in cultures of porcine leukocytes. Vet. Immunol. Immunopathol. 78(1):2001;45-56
48. McCluskie M.J., Davis H.L. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynuclotides as adjuvants. Vaccine. 19(4-5):2000;413-422
49. Heeg K., Zimmermann S. CpG DNA as a Th1 trigger. Int. Arch. Allergy Immunol. 121(2):2000;87-97